ESTRO 2025 - Abstract Book

S2400

Interdisciplinary – Other

ESTRO 2025

Material/Methods The Department of Radiation Oncology data was retrieved and reviewed between July 2019 and June 2024. The records were analyzed for demographic profile, staging details, treatment received, and compliance with treatment. Results A total of 171 oesophageal cancer patients were registered, out of which 96 (56.2%) were males and 75 (43.8%) were females. The cohort's median (IQR) age was 54 (45-64) years. The majority of the patients (125/171; 73%) had locally advanced disease (T3-4/N+), whereas 28 (16%) patients had metastatic disease at presentation. More than 90% (157/171) of patients had thoracic primary, with 20% having gastroesophageal junction involvement. Squamous cell carcinoma (SCC) was the most common pathology in 86% (147/171) patients, followed by adenocarcinoma in 6.5% (11/171) patients. Of all patients, 111 took treatment (any), while 60 defaulted after registration. Neoadjuvant chemoradiotherapy (NACTRT) followed by surgery was planned for 16 patients, but only 4 patients completed it; 10 patients defaulted during treatment (8 after and 2 during NACTRT), while 2 had progressive disease. For the remaining non-metastatic patients (75/171), definitive chemoradiotherapy (CRT) was received by 32 patients, whereas other patients were given upfront chemotherapy. Approximately 20% of patients defaulted after receiving upfront chemotherapy.